Medical device maker Medtronic Plc said on Wednesday Chief Executive Officer Omar Ishrak will retire in April 2020 and will be succeeded by senior executive Geoff Martha.
Ishrak, who will turn 65 next year, spearheaded Medtronic’s nearly $43 billion deal for rival Covidien in 2015, the largest acquisition in the medical technology industry that helped the company redomicile to Ireland, lowering its overall tax burden.
Martha, who will become CEO on April 27 next year, led the integration of Covidien and Medtronic and currently is executive vice president of restorative therapies group (RTG), a unit that sells devices such as spinal implants and robotic surgery systems.
“Investors will be hugely supportive of Geoff taking on the CEO role,” Evercore ISI analyst Vijay Kumar said, noting that it was the right time for the transition.
Martha, who has been with Medtronic since 2011, turned the RTG unit around mainly through the acquisition of Israeli robotics company Mazor Robotics in 2016, which gave Medtronic access to robotic spine surgery system, Mazor X.
The unit generated revenue of more than $8 billion in fiscal 2019, but is Medtronic’s third biggest unit. As a result, Martha’s appointment may be a surprise to some investors, Wells Fargo analyst Larry Biegelsen said, although he does not expect a shift in strategy under Martha in the near term.
From November, Martha will assume a newly created role as Medtronic’s president and join the company’s board. Ishrak will continue as board chairman and will take up a new role as executive chairman of Medtronic after he retires.
Brett Wall, who joined Medtronic from Covidien, will succeed Martha as the executive vice president of the RTG unit.
By Manas Mishra and Manojna Maddipatla
Source: Reuters
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
